Last updated: August 6, 2026
Irbesartan/hydrochlorothiazide is a mature, genericized antihypertensive combination with limited remaining exclusivity, low technical barriers, and high substitution risk. The originator product, Avalide, combined the angiotensin II receptor blocker irbesartan with the thiazide diuretic hydrochlorothiazide. FDA approval dates to 1997, and generic competition has materially compressed pricing and brand value. Current commercial opportunity is concentrated in high-volume, low-margin generic supply, contract manufacturing, pharmacy distribution, and fixed-dose combination portfolios rather than branded innovation.
What is irbesartan and hydrochlorothiazide used for?
Irbesartan/hydrochlorothiazide is an oral fixed-dose combination indicated for hypertension. Irbesartan blocks the angiotensin II type 1 receptor, while hydrochlorothiazide increases renal sodium and water excretion. The combination lowers blood pressure through complementary mechanisms.
The U.S. reference product was Avalide, marketed under NDA 020758. The principal approved strengths were:
| Product strength |
Irbesartan |
Hydrochlorothiazide |
| Lower strength |
150 mg |
12.5 mg |
| Higher strength |
300 mg |
12.5 mg |
The FDA label permits use as initial therapy in selected patients and as replacement therapy for patients already receiving the two components separately. The principal clinical risks are hypotension, renal impairment, electrolyte abnormalities, hyperkalemia from irbesartan, hyponatremia and hypokalemia from hydrochlorothiazide, and fetal toxicity during pregnancy.[1]
How does the combination compare with separate tablets?
The combination improves pill burden and may support adherence, but it does not create a major clinical barrier to substitution. Physicians can prescribe separate irbesartan and hydrochlorothiazide tablets, and many generic suppliers offer both products independently.
Commercially, the fixed-dose combination competes with:
- Irbesartan alone
- Losartan/hydrochlorothiazide
- Valsartan/hydrochlorothiazide
- Telmisartan/hydrochlorothiazide
- Olmesartan/hydrochlorothiazide
- Generic ACE inhibitor/thiazide combinations
- Single-pill calcium-channel blocker and renin-angiotensin-system combinations
The combination's value is therefore based on convenience, formulary position, price, and supply reliability rather than differentiated pharmacology.
When did irbesartan/hydrochlorothiazide lose exclusivity?
Irbesartan/hydrochlorothiazide lost meaningful U.S. commercial exclusivity after the expiry of the relevant irbesartan and combination-product patent protections in the early 2010s. Generic products subsequently entered the U.S. market, and the product now operates in a conventional multisource generic environment.
| Milestone |
Approximate timing |
Commercial effect |
| FDA approval of Avalide |
1997 |
Established the U.S. fixed-dose reference product |
| Brand growth period |
Late 1990s to mid-2000s |
Supported premium pricing and physician familiarity |
| Irbesartan patent expiry period |
Early 2010s |
Opened the active-ingredient market to generic competition |
| Generic fixed-dose combination entry |
Early 2010s |
Reduced Avalide pricing power |
| Mature generic phase |
2010s onward |
Shifted value to manufacturing cost and distribution scale |
The product has no remaining originator-style exclusivity that would support premium U.S. pricing. Any commercial protection now depends on manufacturing efficiency, customer contracts, regulatory approvals, supply continuity, and geographic market access.
What patents protect irbesartan and hydrochlorothiazide?
The historic patent estate centered on irbesartan's active pharmaceutical ingredient, related chemical processes, and the fixed-dose combination. The principal protection period has ended for ordinary U.S. commercial purposes.
Core patent categories
| Patent category |
Historical purpose |
Current commercial relevance |
| Irbesartan compound patents |
Protected the active molecule and its chemical class |
Expired or no longer commercially blocking |
| Process patents |
Covered synthesis routes or intermediates |
May affect manufacturing economics but generally do not block ordinary generic sale |
| Combination patents |
Covered irbesartan with hydrochlorothiazide in defined dosage forms |
No longer a meaningful barrier to U.S. generic competition |
| Method-of-use patents |
Covered treatment of hypertension or related uses |
Limited value because the indication is well established and generic labels can omit protected uses where relevant |
| Formulation patents |
Could cover tablet composition or release characteristics |
Low strategic value for an immediate-release product with multiple generic alternatives |
Public patent databases and Orange Book records should be evaluated by product, jurisdiction, and listing status because historic patents associated with a reference product can remain visible after their commercial blocking effect has ended.[2]
Are formulation patents important for this product?
Formulation patents have limited leverage for irbesartan/hydrochlorothiazide. The product is an immediate-release oral tablet, not a complex delivery system, long-acting injectable, inhaled product, or biologic. Generic manufacturers can generally develop conventional tablets using established excipients and demonstrate bioequivalence through an abbreviated new drug application.
The main technical issues are dissolution, content uniformity, stability, impurity control, and compatibility between the two active ingredients. These requirements create regulatory work but do not create a high barrier comparable with complex drug-device combinations.
What is the Orange Book status of irbesartan/hydrochlorothiazide?
The FDA Orange Book is the primary U.S. source for approved drug products, therapeutic-equivalence evaluations, and listed patents for reference products.[2] Irbesartan/hydrochlorothiazide has been treated as a conventional small-molecule tablet product with generic equivalents.
The relevant commercial indicators are:
- Reference product: Avalide, NDA 020758
- Dosage form: immediate-release tablet
- Regulatory pathway for generics: ANDA
- Expected therapeutic-equivalence framework: AB-rated generic substitution where the FDA assigns the applicable rating
- Biosimilar pathway: not applicable
- Current exclusivity profile: no meaningful originator exclusivity
- Main commercial risk: price erosion and supplier competition, not patent exclusion
A company evaluating a specific product should distinguish between FDA approval, current marketing status, Orange Book patent listings, and actual pharmacy substitution. These are separate legal and commercial questions.
Which companies manufacture or compete in irbesartan/hydrochlorothiazide?
Competition is fragmented across global generic manufacturers, specialty generic suppliers, and large pharmaceutical distributors. U.S. availability has historically included products from companies such as:
- Teva Pharmaceuticals
- Dr. Reddy's Laboratories
- Lupin
- Aurobindo Pharma
- Torrent Pharmaceuticals
- Zydus Pharmaceuticals
- Solco Healthcare
- Major private-label and contract-manufacturing suppliers
The precise active supplier group changes over time because manufacturers enter and exit products, transfer ANDAs, discontinue low-margin presentations, or experience FDA manufacturing actions.
What determines supplier competitiveness?
The main determinants are:
- Tablet manufacturing cost.
- Access to approved active pharmaceutical ingredient suppliers.
- FDA inspection history and remediation status.
- Ability to maintain both 150/12.5 mg and 300/12.5 mg strengths.
- Wholesale acquisition cost and rebate strategy.
- Contract-pharmacy and managed-care relationships.
- Back-up manufacturing capacity.
- Shortage performance and fill-rate reliability.
No single manufacturer has a durable moat based on molecule ownership. Scale, regulatory execution, and supply-chain reliability are more important than intellectual property.
What is the financial trajectory of irbesartan/hydrochlorothiazide?
The financial trajectory follows the standard lifecycle of a primary-care small molecule:
| Phase |
Economic characteristics |
| Launch and adoption |
Premium pricing, physician promotion, branded formulary negotiations |
| Expansion |
Higher prescription volume and broader hypertension use |
| Patent-protected maturity |
Stable revenue with limited new clinical differentiation |
| Generic entry |
Rapid price decline, loss of branded share, lower gross margin |
| Mature generic market |
High unit volume, low per-tablet revenue, periodic supply volatility |
Sanofi and Bristol-Myers Squibb developed and commercialized the irbesartan franchise, including Avalide and the irbesartan-only product Avapro in various markets. Public company reporting generally grouped these products within broader cardiovascular or pharmaceutical sales categories rather than disclosing standalone Avalide revenue.[3][4]
That reporting structure limits the reliability of any current standalone revenue estimate. The economically relevant point is clear: the originator franchise's revenue exposure was front-loaded before generic entry, while current value resides in aggregate generic prescription volume.
Where is the remaining revenue opportunity?
The remaining opportunity is strongest in:
- High-volume retail pharmacy contracts
- Medicaid and Medicare generic formularies
- Private-label supply
- Export markets with slower generic penetration
- Emerging markets where fixed-dose combinations remain underpenetrated
- Dual sourcing and shortage-resilient supply agreements
- Bundled hypertension portfolios
The opportunity is weak in premium branded pricing, physician promotion, or lifecycle management based solely on the existing formulation.
What generic entry risks exist for irbesartan/hydrochlorothiazide?
Generic entry risk is already realized in the U.S. market. A new entrant would face a different risk profile: market crowding and low returns.
Key risks for a new generic entrant
| Risk |
Likely impact |
| Multiple approved suppliers |
Limits achievable price and market share |
| Low reimbursement |
Compresses gross margin |
| API price volatility |
Reduces manufacturing spread |
| FDA inspection or warning letter |
Can interrupt supply and customer contracts |
| Product discontinuation by competitors |
Can create temporary upside |
| Pharmacy consolidation |
Increases buyer bargaining power |
| Hospital and managed-care tenders |
Favors scale and dependable supply |
| Low prescription growth |
Limits volume expansion |
A company entering the product without a differentiated cost position may obtain approval but fail to achieve attractive returns. The strongest entry case usually requires an existing irbesartan or hypertension portfolio, shared manufacturing assets, or a committed buyer.
Were there Paragraph IV challenges and patent litigation?
Paragraph IV litigation was relevant during the transition from branded Avalide and Avapro to generic irbesartan products. Generic applicants could challenge listed patents by asserting that the patents were invalid, unenforceable, or not infringed. The commercial importance of those challenges declined sharply once the principal protection period ended.
The historic dispute environment included challenges involving irbesartan products and related combination products. These cases generally followed the standard ANDA litigation model under the Hatch-Waxman Act, with the reference-product sponsor seeking a stay of FDA approval and the generic applicant seeking clearance to launch.[5]
What is the current litigation status?
There is no widely recognized active U.S. patent dispute that gives Avalide or irbesartan/hydrochlorothiazide a current market-wide exclusionary position. Litigation risk now is more likely to arise from:
- ANDA patent disputes involving a specific supplier
- Product liability claims
- Manufacturing or contamination allegations
- Contract disputes
- Regulatory enforcement
- False-marketing or antitrust claims
Historic settlement agreements, where applicable, should be reviewed in the specific case docket. They do not restore expired patent rights or recreate brand-level exclusivity.
Does irbesartan/hydrochlorothiazide face biosimilar risk?
No. Irbesartan/hydrochlorothiazide is a chemically synthesized small-molecule tablet, not a biologic. Biosimilar regulation under the Public Health Service Act is therefore irrelevant.
The applicable competitive threat is ordinary generic substitution under the Federal Food, Drug, and Cosmetic Act. This generally produces faster and deeper price competition than the market for biologics, where interchangeability, manufacturing complexity, and immunogenicity can slow entry.
How strong is the patent estate for irbesartan/hydrochlorothiazide?
The patent estate is weak as a current commercial defense.
| Strength dimension |
Assessment |
| Active ingredient protection |
Expired or commercially exhausted |
| Fixed-dose combination protection |
Limited current blocking effect |
| Formulation differentiation |
Low |
| Method-of-use protection |
Low for broad hypertension treatment |
| Manufacturing know-how |
Moderate operational value |
| Regulatory exclusivity |
None of strategic significance |
| Litigation leverage |
Low |
| Generic substitution resistance |
Low |
The remaining defensibility is operational. A manufacturer may protect process parameters, yield improvements, impurity controls, supplier qualifications, or manufacturing know-how as trade secrets. Those measures can reduce cost or improve reliability, but they do not prevent competitors from selling bioequivalent tablets.
How does irbesartan/hydrochlorothiazide compare with other antihypertensive combinations?
| Combination |
Commercial maturity |
Competitive intensity |
Differentiation |
| Irbesartan/hydrochlorothiazide |
Mature generic |
High |
Low |
| Losartan/hydrochlorothiazide |
Mature generic |
Very high |
Low |
| Valsartan/hydrochlorothiazide |
Mature generic |
High |
Low |
| Telmisartan/hydrochlorothiazide |
Mature generic |
High |
Low to moderate |
| Olmesartan/hydrochlorothiazide |
Mature generic |
High |
Low |
| Newer branded combination therapies |
Variable |
Lower before expiry |
Potentially higher |
Irbesartan/hydrochlorothiazide has a recognized clinical profile and established prescribing base, but it lacks the patent or formulation protection needed to sustain premium economics. Losartan combinations often have greater generic depth, while newer combinations can command higher prices only before generic entry or when supported by clinical differentiation.
What geographic markets remain commercially attractive?
The U.S. and Western European markets are mature and price-sensitive. Growth potential is more likely in markets where:
- Hypertension diagnosis is increasing.
- Combination therapy is expanding.
- Generic substitution is less aggressive.
- Local manufacturing is favored.
- Distribution remains fragmented.
- Fixed-dose combinations are included in public formularies.
Emerging-market opportunity does not eliminate pricing pressure. Local registration requirements, tender procurement, currency volatility, import controls, and regional manufacturing rules can offset volume growth.
The geographic strategy should therefore prioritize regulatory simplicity, predictable reimbursement, and supply-chain economics rather than headline population size.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers are moderate but manageable. A supplier must control:
- Irbesartan assay and impurity profile
- Hydrochlorothiazide content uniformity
- Tablet dissolution
- Blend segregation
- Stability under heat and humidity
- Packaging moisture protection
- Bioequivalence performance
- API and excipient qualification
The active ingredients are commercially established, and multiple API sources exist. The principal risk is execution failure rather than inability to reproduce the product.
Intellectual property can still matter at the process level in some jurisdictions. A manufacturer must clear local process patents, formulation claims, regulatory exclusivities, and data-protection rules before launch. In the United States, those concerns are materially less restrictive than they were during the brand-protection period.
Key Takeaways
- Irbesartan/hydrochlorothiazide is a mature generic antihypertensive combination.
- Avalide was FDA-approved in 1997 under NDA 020758.
- The principal commercial patent protections ended in the early 2010s.
- No meaningful current U.S. exclusivity protects the combination from generic competition.
- Biosimilar risk does not apply because the product is a small-molecule tablet.
- Formulation and method-of-use patents provide limited current leverage.
- Revenue is no longer a branded-growth story and is not generally reported separately by originator companies.
- The strongest generic opportunities depend on cost, supply reliability, contract access, and geographic selection.
- The principal risks are price compression, buyer concentration, API supply, and regulatory execution.
- The product has low patent strength but continuing operational value within broad hypertension portfolios.
FAQs
Is irbesartan/hydrochlorothiazide still a profitable generic drug?
It can be profitable at scale, but margins are generally low. Profitability depends on manufacturing cost, supply reliability, contract access, and the number of competing approved suppliers.
Is Avalide still protected by patents?
Avalide no longer has commercially meaningful U.S. patent exclusivity. Historic Orange Book listings may remain relevant for legal review, but they do not prevent ordinary generic competition.
Can a generic manufacturer launch irbesartan/hydrochlorothiazide without developing a new clinical trial program?
Yes. The normal U.S. route is an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the reference product. A full clinical efficacy program is generally unnecessary.
Which irbesartan combination has the strongest commercial position?
No combination has a durable patent advantage in the mature generic segment. Commercial strength depends on formulary access, price, supply continuity, and manufacturer scale.
Does hydrochlorothiazide create a meaningful patent barrier?
No. Hydrochlorothiazide is a long-established generic active ingredient. It contributes formulation and quality-control requirements but does not create a meaningful exclusivity barrier.
References
-
U.S. Food and Drug Administration. (2011). Avalide (irbesartan and hydrochlorothiazide) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
Sanofi. (2000-2012). Annual reports and reference documents. Sanofi.
-
Bristol-Myers Squibb Company. (1997-2002). Annual reports. Bristol-Myers Squibb.
-
U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.
